U.S. Cardiac Resynchronization Therapy Market by Type (CRT Pacemaker and CRT Defibrillator), Application (Intraventricular Dyssynchrony, Interventricular Dyssynchrony, and Atrioventricular Dyssynchrony), and End User (Hospitals, Ambulatory Surgical Centers, and Specialized Cardiac Treatment Centers)- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The U.S. Cardiac Resynchronization Therapy market size was valued at US$ 983.3 Million in 2021 and is expected to hit US$ 1.45 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.1% from 2022 to 2030.

Key Takeaways:

  • The study provides an in-depth analysis of the U.S. cardiac resynchronization therapy market size along with the current trends and future estimations to elucidate the imminent investment pockets
  • It offers market analysis from 2021 to 2030, which is expected to enable stakeholders to capitalize on the prevailing opportunities in the U.S. cardiac resynchronization therapy market
  • A comprehensive analysis on country assists to understand the country market and facilitate the strategic business planning and determine prevailing opportunities
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the U.S. cardiac resynchronization therapy market growth

Growth Factors:

Cardiac resynchronization therapy (CRT) is a treatment to assist heart beat with the right rhythm. It uses a pacemaker to restore the normal timing pattern of the heartbeat. CRT is a procedure to implant a device in the chest to make patient's heart's chambers squeeze (contract) efficiently. Cardiac resynchronization therapy is traditionally a treatment for patients who experience heart failure and then develop an arrhythmia. Cardiac resynchronization therapy finds applications in the intraventricular dyssynchrony, interventricular dyssynchrony, and atrioventricular dyssynchrony.

Factors that drive the growth of the CRT market include surge in elderly population, rise in prevalence of cardiovascular diseases (CVDs), increase in technological advances in the CRT pacemakers and CRT defibrillators, and surge in healthcare expenditure in the U.S. For instance, as per the statistics published by Centers for Disease Control and Prevention (CDC), about 6.2 million adults in the U.S. have heart failure. One patient dies every 36 seconds in the U.S. from cardiovascular disease. Heart disease is the leading cause of death for men, women, and individuals of most racial and ethnic groups in the country. Furthermore, around 655,000 Americans die from heart disease each year, which is one in every four deaths.

On the contrary, high cost of CRT therapy as well as the presence of stringent regulations for CRT devices in the U.S. are anticipated to restrain the U.S. cardiac resynchronization therapy market growth during the forecast period.

U.s. Cardiac Resynchronization Therapy Market Segmentation

The U.S. cardiac resynchronization therapy market is categorized into type, application, and end user. On the basis of type, the market is segmented into CRT pacemaker and CRT defibrillator. CRT pacemaker was introduced first within the healthcare industry in 1994. Pacemaker is a small electronic device, implanted below the collarbone and are connected to the heart through wires (leads) to the right chambers of the heart. The CRT defibrillator segment led the market in 2019, and is expected to continue this trend throughout the forecast period attributed to an increase in adoption of CRT defibrillators over CRT pacemakers as well as the launch of technologically advanced CRT defibrillators.

On the basis of application, the U.S. cardiac resynchronization therapy market is classified into intraventricular dyssynchrony, interventricular dyssynchrony, and atrioventricular dyssynchrony. Interventricular dyssynchrony refers to the discordance between the times of right ventricular (RV) and left ventricular (LV) contraction, or delay in segmental wall motion. Intraventricular dyssynchrony is the principal factor responsible for contractile dysfunction, the one most affected by and most predictive of response to resynchronization therapy. The intraventricular dyssynchrony segment spearheaded the market in 2019 in terms of revenue attributed to comparatively higher incidence of intraventricular dyssynchrony among patients with heart failure and left bundle branch block

Report Scope of the U.S. Cardiac Resynchronization Therapy Market

Report Coverage


Market Size in 2021

USD 983.3 Million

Revenue Projection By 2030

USD 1.45 billion

Growth Rate

CAGR of 5.1% from 2022 to 2030

Base Year


Historical data

2017 - 2020

Forecast Period

2022 to 2030

Segments Covered

Type, Application, End User 

Companies Mentioned

 Medtronic plc, Abbott Laboratories, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Lepu Medical Technology (Beijing) Co., Ltd., LivaNova PLC, MEDICO S.p.A., MicroPort Scientific Corporation, OSCOR Inc., and Osypka Medical GmbH.


On the basis of end user, the U.S. cardiac resynchronization therapy market is classified into hospitals, ambulatory surgical centers, and specialized cardiac treatment centers. Being the primary point for diagnosis and treatment of cardiovascular disease coupled with rise in adoption of cardiac resynchronization therapy devices in the hospital settings, the hospital segment is anticipated to witness supremacy throughout the review period.

The cardiac resynchronization therapy market is highly competitive in nature, as major players in this vertical are concentrating on growth strategies such as product launches, mergers and acquisitions (M&As), partnerships and collaborations to gain competitive advantage. For instance, in January 2020, Medtronic plc received CE Mark (Europe) for its Cobalt and Crome portfolio of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy-defibrillators (CRT-D). ICDs monitor heart rhythms and deliver therapy to correct heart rates that are too fast and can lead to sudden cardiac arrest. Cobalt and Crome heart devices deliver the opportunity of a personalized approach to defibrillator therapy. In addition, in July 2020, the U.S. Food and Drug Administration (USFDA) has approved Abbott's next-generation Gallant implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices in the U.S. These devices provide efficient battery longevity and MRI compatibility. In addition, the new devices offer Bluetooth technology and a new patient smartphone app for improved remote monitoring, allowing for increased patient/physician engagement and streamlined communications.

Some of the prominent players in the Cardiac Resynchronization Therapy market include:


Segments Covered in the Report

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at U.S. for the period of 2017 to 2030

  • By Type
    • CRT Pacemaker
    • CRT Defibrillator
  • By Application
    • Intraventricular Dyssynchrony
    • Interventricular Dyssynchrony
    • Atrioventricular Dyssynchrony
  • By End User
    • Hospitals
    • Ambulatory Surgical Centers
    • Specialized cardiac treatment centers

Key Points Covered in U.S. Cardiac Resynchronization Therapy Market Study:

  • Growth of U.S. Cardiac Resynchronization Therapy in 2022
  • Market Estimates and Forecasts (2017-2030)
  • Brand Share and Market Share Analysis
  • Key Drivers and Restraints Shaping Market Growth
  • Segment-wise
  • Competition Mapping and Benchmarking
  • Recommendation on Key Winning Strategies
  • COVID-19 Impact on Demand for U.S. Cardiac Resynchronization Therapy and How to Navigate
  • Key Product Innovations and Regulatory Climate
  • U.S. Cardiac Resynchronization Therapy Consumption Analysis
  • U.S. Cardiac Resynchronization Therapy Production Analysis
  • U.S. Cardiac Resynchronization Therapy and Management